On May, 3 Rexahn Pharmaceuticals, Inc. (RNN) EPS Estimated At $-0.13

April 16, 2018 - By Theresa Judd

On May, 3 is awaited Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN)’s earnings report, as reported by RTT. This year’s EPS analyst estimate is awaited to be $-0.13. That is 35.00 % up compareed to $-0.2 EPS for last year. Analysts at Wall Street see Rexahn Pharmaceuticals, Inc.’s 44.44 % negative EPS growth compared to $-0.09 EPS for last quarter. On during the last trading session the stock decreased $0.015 or 0.92%, reaching $1.615.Rexahn Pharmaceuticals, Inc. has volume of 6,828 shares. Since April 16, 2017 RNN has declined 70.78% and is downtrending. RNN underperformed by 82.33% the S&P500.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer.The company has $51.27 million market cap. The company's clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer.Last it reported negative earnings. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma.

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: